Generation of a High-Affinity Nanobody Against CD147 for Tumor Targeting and Therapeutic Efficacy Through Conjugating Doxorubicin

Frontiers in Immunology

Yinqian Li¹  Yice Xu²  Rifei Li²  Xi Shi³  Xinjie Zhu⁴  Peng Zhou⁵  Yuehua Qiao⁵ 

[1] Artificial Auditory Laboratory of Jiangsu Province, Xuzhou Medical University, Xuzhou, China;;College of Veterinary Medicine, Northwest A&F University, Yangling, China;Key Laboratory of Tropical Biological Resources of Ministry of Education, School of Pharmaceutical Sciences, Hainan University, Haikou, China;Synthetic and Functional Biomolecules Center, College of Chemistry and Molecular Engineering, Peking University, Beijing, China;

关键词: tumor targeting;    nanobody;    CD147;    phage display;    DOX–11-1;   

DOI  :  10.3389/fimmu.2022.852700

来源: DOAJ

【 摘 要 】

CD147, a glycosylated transmembrane protein in the immunoglobulin superfamily, is overexpressed on the surfaces of various tumor cells and promotes cancer cell proliferation, invasion, and metastasis. Nanobodies, characterized by small sizes, high affinities and specificities, and low immunogenicities, are promising diagnostic and therapeutic tools. However, there are few reports on nanobodies that specifically target CD147. In this work, a specific anti-CD147 nanobody has been successfully identified using phage display technology. The tumor target and antitumor effects have also been detected in different CD147-positive tumors in in vitro and in vivo assays, respectively. Meanwhile, it has a synergistic effect for inhibiting 4T1-bearing mice through conjugating doxorubicin. It may afford new strategies for cancer therapies.

【 授权许可】

Unknown